Man Liu, Huiqing Xu, Ying Zhao, Xia Xue, Mingxing Shi, Yuan Wang, Lan Li, Xian Zhang, Yanguang Feng
{"title":"Study on the Effect of Precise Prevention of H-Type Hypertension, Cardiovascular, and Cerebrovascular Risks in Qingyuan District.","authors":"Man Liu, Huiqing Xu, Ying Zhao, Xia Xue, Mingxing Shi, Yuan Wang, Lan Li, Xian Zhang, Yanguang Feng","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To explore the relationship between controlling the development of H-type hypertension and the effectiveness of precision prevention of cardiovascular risk.</p><p><strong>Methods: </strong>518 patients with essential hypertension with hyperhomocysteinemia diagnosed in December 2019 to February 2020 in Qingyuan District Public Hospital were recruited as the experimental sample for prospective analysis and were equally divided into control and experimental groups according to their order of admission, i.e., 259 patients in each group. The control group was treated with antihypertensive drugs only, while the experimental group was given enalapril folic acid tablets (0.8 mg/d) and vitamin B once daily in addition to antihypertensive drugs, and then monitored for plasma Hcy levels, cardiovascular event rates, and survival at one year.</p><p><strong>Results: </strong>After treatment, the plasma Hcy levels of the experimental group were significantly lower than those of the control group (P < .001). During treatment, the total incidence of cardiovascular disease in the experimental group was less than that in the control group (P < .05). One year after the end of treatment, the mortality rate due to cardiovascular disease in the control group was higher than that in the experimental group (P < .05).</p><p><strong>Conclusion: </strong>It is worthwhile to promote the use of targeted management of patients with H-type hypertension to prevent the occurrence of cardiovascular diseases, improve Hcy levels, and stabilize blood pressure levels in patients.</p>","PeriodicalId":7571,"journal":{"name":"Alternative therapies in health and medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alternative therapies in health and medicine","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To explore the relationship between controlling the development of H-type hypertension and the effectiveness of precision prevention of cardiovascular risk.
Methods: 518 patients with essential hypertension with hyperhomocysteinemia diagnosed in December 2019 to February 2020 in Qingyuan District Public Hospital were recruited as the experimental sample for prospective analysis and were equally divided into control and experimental groups according to their order of admission, i.e., 259 patients in each group. The control group was treated with antihypertensive drugs only, while the experimental group was given enalapril folic acid tablets (0.8 mg/d) and vitamin B once daily in addition to antihypertensive drugs, and then monitored for plasma Hcy levels, cardiovascular event rates, and survival at one year.
Results: After treatment, the plasma Hcy levels of the experimental group were significantly lower than those of the control group (P < .001). During treatment, the total incidence of cardiovascular disease in the experimental group was less than that in the control group (P < .05). One year after the end of treatment, the mortality rate due to cardiovascular disease in the control group was higher than that in the experimental group (P < .05).
Conclusion: It is worthwhile to promote the use of targeted management of patients with H-type hypertension to prevent the occurrence of cardiovascular diseases, improve Hcy levels, and stabilize blood pressure levels in patients.
期刊介绍：
Launched in 1995, Alternative Therapies in Health and Medicine has a mission to promote the art and science of integrative medicine and a responsibility to improve public health. We strive to maintain the highest standards of ethical medical journalism independent of special interests that is timely, accurate, and a pleasure to read. We publish original, peer-reviewed scientific articles that provide health care providers with continuing education to promote health, prevent illness, and treat disease. Alternative Therapies in Health and Medicine was the first journal in this field to be indexed in the National Library of Medicine. In 2006, 2007, and 2008, ATHM had the highest impact factor ranking of any independently published peer-reviewed CAM journal in the United States—meaning that its research articles were cited more frequently than any other journal’s in the field.
Alternative Therapies in Health and Medicine does not endorse any particular system or method but promotes the evaluation and appropriate use of all effective therapeutic approaches. Each issue contains a variety of disciplined inquiry methods, from case reports to original scientific research to systematic reviews. The editors encourage the integration of evidence-based emerging therapies with conventional medical practices by licensed health care providers in a way that promotes a comprehensive approach to health care that is focused on wellness, prevention, and healing. Alternative Therapies in Health and Medicine hopes to inform all licensed health care practitioners about developments in fields other than their own and to foster an ongoing debate about the scientific, clinical, historical, legal, political, and cultural issues that affect all of health care.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
